Filming and expert interviews at ASCO GU 2013

Written by Victoria Louise Crump-Haill – Digital Strategist/Account Director‏

The Brandcast Health team had a busy week in Orlando interviewing and filming some of the world’s leading prostate cancer experts at the 2013 ASCO Genitourinary Cancers Symposium. Below are some great interviews published for the Audio Journal of Oncology.

Low risk prostate cancer: less treatment means lower cost, and better patient outcomes

ORLANDO, FLORIDA—Patients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston MA — a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he noted, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.

Low risk localized prostate cancer: no harm from waiting!

ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre in Toronto. His group’s research has found that the rate of “migration” of Gleason grade — representing disease progression — was gradual: accounting for no more than a third of patients developing a form of the disease requiring treatment within ten years. The remaining patients can be spared the side effects of treatment.

Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months but have fewer side effects — according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando by Dr Abdenour Nabid from Sherbrooke University in Quebec.

Comments are closed.


We'd love to work with you

Contact Us

16-17 Little Portland Street

+44 (0)20 7291 5070


8 Cross Street, Level 28
PWC Building
Singapore, 048424

+44 (0)20 7291 5070

Suffolk Coast

Basepoint Unit 12a
The Havens
Ransomes Euro Park
Ipswich, IP3 9BF

T. +44 (0)1473 722 794

Call Us